NEW ANGIOGENIC AND OSTEOGENIC PULLULAN-DEXTRAN PRODUCTS FOR SEGMENTAL BONE DEFECT TREATMENT IN ORTHOPEDIC AND ORAL SURGERY. – GlycoMb

The treatment of segmental bone lesions is a challenge for orthopedic and maxillofacial surgeons who use therapeutic solutions that cause morbidity and high costs for society.

Based on the results obtained from an existing partnership which result to a patent and the creation of the company SilTiss, the objective of this project is to develop two innovative products for bone regeneration:
- a new bone tissue regeneration membrane based on polysaccharides (pullulan - dextran) and hydroxyapatite particles
- a new bone substitute based on micro-beads made up of the same components (Glycobone®) loaded with natural ingredients active on the secretion of VEGF and periostin, two key players in bone regeneration.

We hypothesize that the combination of these two products will allow to treat segmental bone defects with greater efficiency than the induced membrane technique which is one of the reference techniques for the treatment of segmental bone defects in orthopedic and maxilla-facial surgery.

This combination of Membrane / Glycobone® loaded with angiogenic and osteogenic active ingredients will be developed in partnership between:
- two INSERM units (U1148-U1026) with expertise in the development of biomaterials and their validation in vitro and in vivo and,
- two companies (SILAB and its subsidiary SILTISS) with expertise in the production of natural active ingredients and the development of plant-based medical devices.

The proof of concept of the therapeutic effect of the combination of the membrane and the beads will be done in two models of segmental bone defect in orthopedic surgery and in maxillofacial surgery.

This project will have a medical impact on patient care by simplifying treatment procedures and an economic impact by reducing the costs associated with multiple procedures and their complications.